Ellis Martin Report: Echo IQ Limited (ECHQF) CEO Dustin Haines on FDA Progress and AI in Healthcare
In this episode of The Ellis Martin Report, CEO Dustin Haines of Echo IQ Limited (ASX:EIQ) (OTCMKTS:ECHQF) discusses how artificial intelligence is transforming the early detection of cardiovascular disease.
Echo IQ is pioneering AI-driven diagnostic tools designed to help physicians detect heart conditions earlier and more accurately. With FDA clearance already secured for its aortic stenosis solution and a second product for heart failure currently under review, the company is positioning itself at the forefront of AI-powered healthcare innovation.
In this interview, Dustin Haines shares insights on:
- Echo IQ's rapid growth and global expansion
- FDA progress and upcoming catalysts
- Breakthrough heart failure detection with ~99.5% sensitivity
- The future of AI in healthcare, including wearables and predictive diagnostics
- Why cardiovascular disease remains a massive global opportunity
With over 200 million echocardiogram evaluations and collaborations with leading institutions like the Mayo Clinic, Echo IQ is aiming to redefine how heart disease is diagnosed and managed.
Learn more: https://www.echoiq.ai
Dustin Haines Dustin.Haines@echoiq.ai
News Provided by ABN Newswire
